Actuate Therapeutics, Inc. · NASDAQ:ACTU

Actuate Therapeutics — STIFEL 2023 Targeted Oncology Days

16 slides from Actuate Therapeutics's conference presentation, Apr 26, 2023

  1. Slide 1: STIFEL 2023 Targeted Oncology Days

    STIFEL 2023 Targeted Oncology Days Daniel M. Schmitt, President & CEO April 26, 2023 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements ► This presentation contains forward looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future

  3. Slide 3: Company Highlights

    Company Highlights ✓ Clinical stage oncology focused company in multiple advanced cancer phase 2 trials Clinical responses (CRs/PRs) and Disease Control across multiple cancer ✓ histologies with elraglusib (9-ING-41) IV as single agent and in combination ✓ Survival benefit in key diseases including

  4. Slide 4: Multimodal MOA Distinguishes Elraglusib from Other GSK-3 Inhibitors

    Multimodal MOA Distinguishes Elraglusib from Other Glycogen Synthase Kinase (GSK-3) Inhibitors lmmunomodulatory effects, inhibition of cancer cell proliferation and survival, regulation of epithelial-mesenchymal transition (EMT) and fibrosis in multiple cellular compartments contribute to antitumor

  5. Slide 5: Clinical Study 1801 - Phase 1/2 Study Design

    Clinical Study 1801 - Phase 1/2 Study Design Part 3 – Seamless Initiation of Phase 2 Efficacy Studies Based on Part 1 and 2 Results Part 1 Monotherapy Dose Escalation of Single Agent Elraglusib Part 2 Dose Escalation of Elraglusib in Combination with Standard Chemotherapy All patients required to ha

  6. Slide 6: Complete Response in Melanoma

    Complete Response in Melanoma First Clinical Evidence of Immune Modulator Effects of Elraglusib First objective response reported in cohort 4 (5 mg/kg) in a patient with metastatic melanoma • 55 year old male diagnosed with metastatic melanoma in 2018 12 weeks on elraglusib • Widely metastasized to

  7. Slide 7: 1801 Arm A – Preliminary OS Analysis

    1801 Arm A – Preliminary OS Analysis KAPLAN MEIER – OS: 1801 PANCREATIC PATIENTS (evaluable) ✓ Disease control in 1801 Parts 1 and 2 and in PDAC Part 3 suggests immune modulator activity •Typical Phase 1 population associated with rapid progression and short overall survival •Traditional response cr

  8. Slide 8: Phase 2 Clinical RCT in First Line Treatment of Metastatic PDAC

    Phase 2 Clinical RCT in First Line Treatment of Metastatic PDAC Randomized Control Trial compares Gem/Abraxane versus combination with elraglusib Run-in: Elraglusib schedule 1801 PANCREATIC PATIENTS (ITT) – TIME ON STUDY determined by a randomized three arm run-in that compared: Gem-Abraxane (GnP) Q

  9. Slide 9: Phase 2 Clinical RCT in First Line Metastatic PDAC: Survival Data

    Phase 2 Clinical RCT in First Line Treatment of Metastatic PDAC Open Label Randomized Control Trial compares Gem/Abraxane versus combination with elraglusib 1801 PANCREATIC PATIENTS (mITT) - KAPLAN MEIER - PFS 1801 PANCREATIC PATIENTS (mITT) - KAPLAN MEIER - OS Part 3 Arm OS 100 GA only GnP 100 Prob

  10. Slide 10: Elra + FOLFIRINOX in First Line PDAC-Initial Results from IIT Study

    Elra + FOLFIRINOX in First Line PDAC-Initial Results from IIT Study • Metastatic Pancreatic Cancer (1st line) • FOLFIRINOX+losartan+elraglusib (RCT) Patient A-001 Patient A-003 • IIT at Mass General / Fred Hutchinson (Lustgarten Foundation) • Tox run-in recently completed (n=6). Patients characteriz

  11. Slide 11: Actuate Development Pipeline-Enrolling and Planned Studies

    Actuate Development Pipeline-Enrolling and Planned Studies Indication Phase 1 Phase 2 Phase 3 Upcoming Milestones Pancreatic Cancer (Fast track designation) • Elraglusib (Elra) + gem/Abraxane (1st line, Topline Data – 1Q24 Study 1801 Extension (enrolling) randomized) • Elra + FOLFIRINOX + Losartan S

  12. Slide 12: Elraglusib Oral Formulations – PK Profiles

    Elraglusib Oral Formulations – PK Profiles Oral elraglusib formulations have been developed that provide similar drug exposures to current IV • Several viable oral dosage forms will allow potential expansion into pediatric cancer indications and adult indications where standard of care is oral (e.g.

  13. Slide 13: Actuate Issued Patent Portfolio

    Actuate Issued Patent Portfolio International • 9-ING-41 Polymorph I Composition of Matter: Patent Issued (10/5/2021) US 11,136,334 • Patent Application No. PCT/US2018/046203, filed August 10, 2018 • Expires August 10, 2038, Potentially Eligible for Patent Term Extension (PTE) • Claims directed to P

  14. Slide 14: Seasoned and Successful Executive Leadership

    Seasoned and Successful Executive Leadership Experienced leadership team with demonstrated ability to develop and commercialize cancer drugs Daniel M. Schmitt – Chief Executive Officer and Founder • 30+ years of biotechnology and pharmaceutical experience across senior executive roles • Led and cont

  15. Slide 15: Actuate Therapeutics Summary

    Actuate Therapeutics Summary Best-in-Class Therapeutic Profile Robust IP Portfolio Extensive pre-clinical demonstration of Expansive, global patent portfolio • Composition of matter and methods of use activity from multiple laboratories and surrounding Elraglusib’s formulation and positive clinical

  16. Slide 16: Actuate Therapeutics

    ACTUATE HERAPEUTICS

Actuate Therapeutics — STIFEL 2023 Targeted Oncology Days on 6ix